论文部分内容阅读
目的：评价诺迪康胶囊治疗冠状动脉粥样硬化性心脏病（冠心病）的临床疗效及其对血小板聚集率的影响。方法：４６例冠心病患者随机分２组，分别服用诺迪康胶囊和复方丹参片４周；治疗前后进行心电图和血小板聚集率（ＰＡＲ）检查。结果：３０例患者服诺迪康胶囊前后ＰＡＲ分别为０．７３±０．１５和０．６３±０．１２（Ｐ＜０．０１），与对照组治疗后（０．６９±０．１５）比较有显著性差异（Ｐ＜０．０５），心绞痛临床总有效率为９０．０％，明显高于对照组６２．５％（Ｐ＜０．０５），心电图改善总有效率（６１．５％）高于对照组（５３．９％），但无显著差异。结论：诺迪康胶囊可明显降低ＰＡＲ，改善胸痛症状及心电图ＳＴＴ改变。
Objective: To evaluate the clinical efficacy of Nordicum capsule in treating coronary atherosclerotic heart disease (CHD) and its effect on platelet aggregation rate. Methods: Forty-six patients with coronary heart disease were randomly divided into two groups, taking Nuodikang capsules and Fufang Danshen tablets for 4 weeks respectively. The electrocardiogram and platelet aggregation rate (PAR) were measured before and after treatment. Results: The PAR of 30 patients before and after treatment with Nuodendron capsules were 0.73 ± 0.15 and 0.63 ± 0.12 (P <0.01), respectively, which were significantly lower than those of the control group (0.69 ± 0.15 (P <0.05). The total clinical effective rate of angina pectoris was 90.0%, which was significantly higher than that of the control group (62.5%, P <0.05). The electrocardiogram improved the total effective rate (61. 5%) than the control group (53.9%), but no significant difference. Conclusion: Nuodikang capsules can significantly reduce PAR, improve the symptoms of chest pain and electrocardiogram STT changes.